stockrow
Friday 6 November 2026
Export QGEN’s income statement to Excel — free account
QIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
50.31
0.55
−1.08%
Follow QGEN
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
24.28 | 23.48 | 20.91 | 20.03 |
P/S ratio |
4.68 | 4.92 | 3.95 | 3.84 | |
P/FCF ratio |
20.51 | 22.99 | 20.52 | 18.31 | |
P/Operating CF |
58.72 | 54.66 | 82.37 | 40.20 | |
P/B ratio |
2.66 | 2.72 | 2.49 | 2.40 | |
Price to Tangible BV |
12.15 | 14.88 | 30.90 | 25.86 | |
EV/Sales |
4.89 | 5.43 | 4.66 | 4.25 | |
EV/EBITDA |
14.87 | 17.10 | 15.31 | 13.70 | |
EV/Operating CF |
15.40 | 17.33 | 15.91 | 13.63 | |
EV/FCF |
21.43 | 25.35 | 24.24 | 20.24 | |
Quick Ratio |
2.12 | 2.93 | 2.18 | 2.04 | |
Current Ratio |
2.60 | 3.90 | 3.21 | 2.85 | |
Net Debt/EBITDA |
2.41 | 3.71 | 7.34 | 4.63 | |
Debt/Assets |
32.46% | 26.34% | 28.48% | 27.91% | |
Debt/Equity |
0.58 | 0.44 | 0.49 | 0.49 | |
Asset Turnover |
0.32 | 0.35 | 0.37 | 0.36 | |
Operating CF/Net income |
1.27 | 1.74 | 1.48 | 1.94 | |
Capex/Depreciation |
(0.97) | (1.42) | (0.94) | (0.85) | |
Interest Coverage |
15.72 | 9.81 | 7.64 | 13.21 | |
Research and Development Expense of Revenue |
9.15% | 8.74% | 9.80% | 9.43% | |
Selling, General and Administrative Expense of Revenue |
26.87% | 28.47% | 28.92% | 27.43% | |
Intangible Assets out of Total Assets |
0.44 | 0.49 | 0.53 | 0.52 | |
Share Based Compensation of Revenue |
2.01% | 3.07% | 1.96% | 1.30% | |
Graham Net Nets |
(0.04) | (0.05) | (0.11) | (0.11) | |
Graham Number |
27.78 | 28.09 | 26.33 | 26.73 | |
Earnings Yield |
4.12% | 4.26% | 4.78% | 4.99% | |
Free Cash Flow Yield |
4.88% | 4.35% | 4.87% | 5.46% | |
Revenue per Share |
2.59 | 2.49 | 2.38 | 2.59 | |
Operating CF per Share |
0.80 | 0.87 | 0.49 | 0.97 | |
Capex per Share |
(0.24) | (0.33) | (0.23) | (0.21) | |
Free Cash Flow per Share |
0.56 | 0.54 | 0.25 | 0.76 | |
Cash per Share |
8.20 | 5.06 | 3.12 | 3.85 | |
Shareholders Equity per Share |
17.71 | 17.39 | 16.09 | 16.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.71 | 17.39 | 16.09 | 16.27 | |
Free Cash Flow |
114.57 | 116.55 | 52.15 | 157.32 | |
Working Capital |
1,557.53 | 1,482.94 | 1,061.14 | 1,075.18 | |
Capital Expenditures |
(50.45) | (71.58) | (48.48) | (43.37) | |
Net Current Asset Value |
(373.14) | (508.00) | (910.10) | (874.83) | |
EV/EBIT |
20.86 | 24.34 | 22.51 | 20.02 | |
Capex to Sales |
0.09 | 0.13 | 0.10 | 0.08 | |
Price to Operating Income |
19.96 | 22.07 | 19.06 | 18.11 | |
| Other line items | |||||
Average Receivables |
360.57 | 375.94 | 368.66 | 387.80 | |
Average Payables |
76.89 | 77.96 | 73.98 | 80.71 | |
Average Inventory |
305.96 | 290.57 | 295.49 | 301.95 | |
Average Assets |
6,411.85 | 5,985.43 | 5,663.72 | 5,856.48 | |
Average Common Equity |
3,589.70 | 3,672.75 | 3,369.79 | 3,431.62 |
Columns are period end dates · fundamentals updated 25 Oct 2026